Virax Biolabs Group Ltd Cash And Cash Equivalents
Virax Biolabs Group Ltd (VRAX) had Cash And Cash Equivalents of $4.23 million as of 2025-03-31, per its 20-F filed 2025-07-02.
Financial Statements › Notes
ifrs-full:CashAndCashEquivalents · last filed 2025-07-02
- 2025-03-31: Cash And Cash Equivalents $4.23M.
- 2024-03-31: Cash And Cash Equivalents $3.59M.
- 2023-03-31: Cash And Cash Equivalents $9.35M.
- 2022-03-31: Cash And Cash Equivalents $21.76K.
| Period end | Cash And Cash Equivalents |
|---|---|
| 2025-03-31 | $4.23M 20-F · filed 2025-07-02 |
| 2024-03-31 | $3.59M 20-F · filed 2025-07-02 |
| 2023-03-31 | $9.35M 20-F · filed 2025-07-02 |
| 2022-03-31 | $21.76K 20-F · filed 2025-07-02 |
| 2021-04-01 | $17.62K 20-F · filed 2022-08-12 |
| 2021-03-31 | $17.62K 20-F · filed 2024-08-20 |
| 2020-04-01 | $22.61K 20-F · filed 2022-08-12 |